[2020 ESC Guidelines on Atrial Fibrillation : Summary of the Most Relevant Recommendations and Innovations]

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2020 Dec 8

PMID 33289046

Citations 7

Authors

Alireza Sepehri Shamloo

Nikolaos Dagres

Gerhard Hindricks

Affiliations

Soon will be listed here.

Abstract

The new guidelines for the diagnosis and management of atrial fibrillation (AF) were published by the European Society of Cardiology (ESC) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) in August 2020. The 2020 guidelines of the ESC on AF summarize the current developments in this field and provide general recommendations for the management of patients with AF based on the principles of evidence-based medicine. Beside the general statements on definition, epidemiology and clinical features of AF, interesting new aspects in screening and diagnosis of AF are also presented. The main novelties of the 2020 guidelines are the proposal of the 4S-AF scheme for a structured characterization of AF that takes the stroke risk, severity of symptoms, severity of AF burden and substrate severity into account. Also new is the ABC approach for improvement of the structured management and treatment results. A further innovation is the introduction of the concept of major risk factors for recurrences in the decision for catheter ablation. This review focuses on the newest and most important recommendations taken from the 2020 ESC guidelines for the diagnosis and management of AF.

Citing Articles

Gene Polymorphism and Recurrent Atrial Fibrillation after Catheter Ablation: A Comprehensive Review.

Wang M, Xue C, Shi S, Yang L, Zhu Z, Li J Rev Cardiovasc Med. 2024; 24(4):119.

PMID: 39076272 PMC: 11273024. DOI: 10.31083/j.rcm2404119.

Management of cerebral amyloid angiopathy and atrial fibrillation: We are still far from precision medicine.

Fusco L, Palama Z, Scara A, Borrelli A, Robles A, De Masi De Luca G World J Cardiol. 2024; 16(5):231-239.

PMID: 38817646 PMC: 11135332. DOI: 10.4330/wjc.v16.i5.231.

Effect of China national centralized drug procurement policy on anticoagulation selection and hemorrhage events in patients with AF in Suining.

Zhang Q, Wang R, Chen L, Chen W Front Pharmacol. 2024; 15:1365142.

PMID: 38444941 PMC: 10912648. DOI: 10.3389/fphar.2024.1365142.

The Differences of Quantitative Flow Ratio in Coronary Artery Stenosis with or without Atrial Fibrillation.

Lu W, Zhang X, Yan G, Ma G J Interv Cardiol. 2023; 2023:7278343.

PMID: 37868769 PMC: 10589068. DOI: 10.1155/2023/7278343.

Development and Validation of a Nomogram Model Affecting the ACT Targeting Rate During Radiofrequency Ablation of Atrial Fibrillation in China.

Tang S, Hu X, Bao W, Li F, Ge L, Wei H Cardiovasc Drugs Ther. 2023; 38(6):1201-1214.

PMID: 37160503 DOI: 10.1007/s10557-023-07450-3.

References

Dagres N, Peek N, Leclercq C, Hindricks G . The PROFID project. Eur Heart J. 2020; 41(39):3781-3782. PMC: 7599031. DOI: 10.1093/eurheartj/ehaa645. View

Lubitz S, Benjamin E, Ruskin J, Fuster V, Ellinor P . Challenges in the classification of atrial fibrillation. Nat Rev Cardiol. 2010; 7(8):451-60. PMC: 3073055. DOI: 10.1038/nrcardio.2010.86. View

Sepehri Shamloo A, Bollmann A, Dagres N, Arya A, Hindricks G . Smart Watch Devices for Atrial Fibrillation Screening: It Has to Start Somewhere. J Am Coll Cardiol. 2020; 75(11):1364-1365. DOI: 10.1016/j.jacc.2019.10.063. View

Nielsen J, Lin Y, de Oliveira Figueiredo M, Sepehri Shamloo A, Alfie A, Boveda S . European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right.... Europace. 2020; 22(8):1147-1148. PMC: 7400488. DOI: 10.1093/europace/euaa065. View

Wynn G, Todd D, Webber M, Bonnett L, McShane J, Kirchhof P . The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014; 16(7):965-72. PMC: 4070972. DOI: 10.1093/europace/eut395. View

Lip G, Nieuwlaat R, Pisters R, Lane D, Crijns H . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2009; 137(2):263-72. DOI: 10.1378/chest.09-1584. View

Lip G . The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017; 14(11):627-628. DOI: 10.1038/nrcardio.2017.153. View

Van Gelder I, Rienstra M, Crijns H, Olshansky B . Rate control in atrial fibrillation. Lancet. 2016; 388(10046):818-28. DOI: 10.1016/S0140-6736(16)31258-2. View

Ecker V, Knoery C, Rushworth G, Rudd I, Ortner A, Begley D . A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation. Clin Cardiol. 2018; 41(6):862-870. PMC: 6489932. DOI: 10.1002/clc.22931. View

10.

Shiga T, Yoshioka K, Watanabe E, Omori H, Yagi M, Okumura Y . Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide. J Arrhythm. 2017; 33(4):310-317. PMC: 5529594. DOI: 10.1016/j.joa.2017.03.005. View

11.

Singh B, Singh S, Reda D, Tang X, Lopez B, Harris C . Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005; 352(18):1861-72. DOI: 10.1056/NEJMoa041705. View

12.

Capucci A, Piangerelli L, Ricciotti J, Gabrielli D, Guerra F . Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation. Europace. 2016; 18(11):1698-1704. DOI: 10.1093/europace/euv462. View

13.

Siontis K, Ioannidis J, Katritsis G, Noseworthy P, Packer D, Hummel J . Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation: Meta-Analysis of Quality of Life, Morbidity, and Mortality. JACC Clin Electrophysiol. 2018; 2(2):170-180. DOI: 10.1016/j.jacep.2015.10.003. View

14.

Kim Y, Shim J, Choi J, Kim Y . Radiofrequency Catheter Ablation Improves the Quality of Life Measured with a Short Form-36 Questionnaire in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(9):e0163755. PMC: 5040266. DOI: 10.1371/journal.pone.0163755. View

15.

Kirchhof P, Camm A, Goette A, Brandes A, Eckardt L, Elvan A . Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020; 383(14):1305-1316. DOI: 10.1056/NEJMoa2019422. View

16.

Hindricks G, Sepehri Shamloo A, Lenarczyk R, Kalarus Z, Arya A, Kircher S . Catheter ablation of atrial fibrillation: current status, techniques, outcomes and challenges. Kardiol Pol. 2018; 76(12):1680-1686. DOI: 10.5603/KP.a2018.0216. View

17.

Baranchuk A, Yeung C . Advanced interatrial block predicts atrial fibrillation recurrence across different populations: Learning Bayés syndrome. Int J Cardiol. 2018; 272:221-222. DOI: 10.1016/j.ijcard.2018.08.025. View

18.

Toufan M, Kazemi B, Molazadeh N . The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion. J Cardiovasc Thorac Res. 2017; 9(1):54-59. PMC: 5402028. DOI: 10.15171/jcvtr.2017.08. View

19.

Calkins H, Hindricks G, Cappato R, Kim Y, Saad E, Aguinaga L . 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace. 2017; 20(1):157-208. PMC: 5892164. DOI: 10.1093/europace/eux275. View

20.

Lane D, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan G, Hills M . Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad.... Europace. 2015; 17(12):1747-69. DOI: 10.1093/europace/euv233. View